Characteristic | Total sample (N = 2313) | Cannabis non-user (n = 1135) | Cannabis user (n = 1178) |
---|---|---|---|
Demographic | |||
Age in years; mean (SD) | 39.3 (10.9) | 40.9 (10.9) | 37.7 (10.6) |
Female sex; n (%) | 1025 (44.3%) | 557 (49.1%) | 468 (39.7%) |
Married; n (%) | 673 (29.1%) | 356 (31.4%) | 317 (26.9%) |
Unemployed; n (%) | 1548 (66.9%) | 761 (67.1%) | 787 (66.8%) |
Clinical | |||
Length of time in treatment, in years; median (Q1, Q3) | 2.6 years (0.83, 6) | 3 years (0.92, 7) | 2 years (0.75, 6) |
Type of treatment; n (%) | |||
Methadone | 1833 (79.4%) | 890 (78.6%) | 944 (80.1%) |
Buprenorphine–naloxone | 477 (20.7%) | 243 (21.5%) | 234 (19.9%) |
Medication dose in mg/day; mean (SD) | |||
Methadone | 70.4 mg (40.6) | 72.9 mg (41.3) | 68.1 mg (39.8) |
Buprenorphine–naloxnaloxone | 12 mg (6.8) | 12 mg (7.0) | 12 mg (6.6) |
Opioid use at 3 monthsa; n (%) | 1015 (44.8%) | 488 (44.0%) | 527 (44.7%) |
Percentage of opioid-positive urine drug screens amongst users; median (Q1, Q3) | 25 (11.1, 50) | 30 (12.5, 55.6) | 21.4 (10, 50) |